Reduction in cardiovascular disease events in patients with type 2 diabetes mellitus treated with a sodium–glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase‐4 inhibitor: A real‐world retrospective administrative database analysis in Japan
Open Access
- 9 April 2022
- journal article
- research article
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 13 (7) , 1175-1189
Abstract
Aims/Introduction: To evaluate the benefit of sodium–glucose cotransporter 2 inhibitors (SGLT2i) versus dipeptidyl peptidase‐4 inhibitors (DPP4i) in reducing cardiovascular disease (CVD) events in patients with type 2 diabetes mellitus with and without a CVD history.Materials and Methods: This retrospective cohort study used Japanese hospital administrative data from the Medical Data Vision database (January 2015 to April 2020). Patients with type 2 diabetes mellitus (n = 625,739) who were new users of an SGLT2i (n = 57,070; 9.1%) or DPP4i (n = 568,669; 90.9%) were included. Outcomes included hospitalization for heart failure (hHF), all‐cause death (ACD) and the composite of hHF or ACD. Hazard ratios (HR) were calculated using the inverse probability weighting Cox proportional hazards model to compare CVD event risks between treatment groups.Results: Compared with DPP4i, SGLT2i was associated with a significant reduction in hHF risk among patients without a CVD history (HR 0.507, 95% confidence interval 0.283–0.907), but not in the full cohort or those with a CVD history. SGLT2i was associated with a significant risk reduction of ACD (HR 0.592, 95% confidence interval 0.481–0.729) and the composite of hHF or ACD (HR 0.712, 95% confidence interval 0.613–0.826), compared with DPP4i in the full cohort; similar results were observed among patients with and without a CVD history.Conclusions: In this real‐world study, SGLT2i versus DPP4i was associated with a significant reduction in hHF, ACD and hHF or ACD events in patients with type 2 diabetes mellitus without a CVD history.Keywords
Funding Information
- Astellas Pharma US
This publication has 26 references indexed in Scilit:
- Canagliflozin and Heart Failure in Type 2 Diabetes MellitusCirculation, 2018
- SGLT-2 Inhibitors and Cardiovascular RiskJACC, 2018
- Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering DrugsJACC, 2018
- Reduced Mortality With Sodium-Glucose Cotransporter–2 Inhibitors in Observational StudiesCirculation, 2018
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine, 2017
- Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering DrugsCirculation, 2017
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Pharmacoepidemiology in Japan: medical databases and research achievementsJournal of Pharmaceutical Health Care and Sciences, 2015
- Ipragliflozin: First Global ApprovalDrugs, 2014
- Validating the adapted Diabetes Complications Severity Index in claims data.2012